Welcome to LookChem.com Sign In|Join Free

CAS

  • or

2267-40-5

Post Buying Request

2267-40-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2267-40-5 Usage

Description

3-CHLOROSULFONYL-4-FLUORO-BENZOIC ACID is a chemical compound characterized by its molecular formula C7H4ClFO4S. It manifests as a white crystalline solid with a melting point of 160-162°C. 3-CHLOROSULFONYL-4-FLUORO-BENZOIC ACID is distinguished by its functional groups, including chlorosulfonyl and fluorobenzoic acid, which contribute to its strong acidity and reactivity. These properties render it a valuable intermediate in the synthesis of pharmaceuticals and agrochemicals, making it a versatile reagent for organic synthesis.

Uses

Used in Pharmaceutical Industry:
3-CHLOROSULFONYL-4-FLUORO-BENZOIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique functional groups facilitate the creation of new drug molecules, contributing to the development of novel treatments for a range of medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 3-CHLOROSULFONYL-4-FLUORO-BENZOIC ACID serves as an essential intermediate for the production of crop protection agents. Its reactivity allows for the synthesis of compounds that can effectively protect crops from pests and diseases, thereby enhancing agricultural productivity and crop yields.
Used in Organic Synthesis:
3-CHLOROSULFONYL-4-FLUORO-BENZOIC ACID is utilized as a versatile reagent in organic synthesis. Its strong acidity and reactivity make it suitable for a wide range of chemical reactions, enabling the synthesis of various organic compounds for different applications across multiple industries.

Check Digit Verification of cas no

The CAS Registry Mumber 2267-40-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,6 and 7 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 2267-40:
(6*2)+(5*2)+(4*6)+(3*7)+(2*4)+(1*0)=75
75 % 10 = 5
So 2267-40-5 is a valid CAS Registry Number.
InChI:InChI=1/C7H4ClFO4S/c8-14(12,13)6-3-4(7(10)11)1-2-5(6)9/h1-3H,(H,10,11)

2267-40-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-chlorosulfonyl-4-fluorobenzoic acid

1.2 Other means of identification

Product number -
Other names 3-chlorosulfonyl-4-fluoro-benzoic Acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2267-40-5 SDS

2267-40-5Relevant articles and documents

Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication

Lee, Yeon Hee,Cha, Hyeon-Min,Hwang, Jun Yeon,Park, So Yeong,Vishakantegowda, Avinash G.,Imran, Ali,Lee, Joo-Youn,Yi, Yoon-Sun,Jun, Sangmi,Kim, Ga Hyeon,Kang, Hyo Jin,Chung, Sang J.,Kim, Meehyein,Kim, Hyejin,Han, Soo Bong

supporting information, p. 242 - 248 (2021/02/20)

As the spread of infections caused by hepatitis B virus (HBV) threatens public health worldwide, investigations from multiple perspectives and of various mechanisms of action are urgently required to increase the HBV cure rate. Targeting the encapsidation of the nuclear capsid protein (core protein, HBc) has emerged as an attractive strategy for inhibiting the viral assembly process; however, a drug targeting this mechanism has not yet been approved. We synthesized novel sulfamoylbenzamides (SBAs) as capsid assembly modulators of HBV and found that the effects and safety profiles of compounds 3 and 8 have potential therapeutic applicability against HBV. The formation of tubular particles was time-dependent in the presence of 3, indicating a new mode of protein assembly by SBA compounds. Our findings provide a new entity for developing safe and efficient treatments for HBV infection.

Synthesis of a new series of 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides as carbonic anhydrase I, II, IV and IX inhibitors

Swain, Baijayantimala,Angeli, Andrea,Angapelly, Srinivas,Thacker, Pavitra S.,Singh, Priti,Supuran, Claudiu T.,Arifuddin, Mohammed

, p. 1199 - 1209 (2019/07/02)

The synthesis of a novel series of 3-functionalised benzenesulfonamides incorporating phenyl-1,2,3-triazole with an amide linker was achieved by using the “click-tail” approach. The new compounds, including the intermediates, were assayed as inhibitors of human carbonic anhydrase (CA, EC 4.2.1.1) isoforms hCA I and II (cytosolic isoforms) and also for hCA IV and IX (transmembrane isoforms) taking acetazolamide as standard drug. Most of these compounds exhibited excellent activity against all these isoforms. hCA I was inhibited with Kis in the range of 50.8–966.8 nM, while the glaucoma associated hCA II was inhibited with Kis in the range of 6.5–760.0 nM. Isoform hCA IV was inhibited with Kis in the range of 65.3–957.5 nM, whereas the tumor associated hypoxia induced hCA IX was inhibited with Kis in the range of 30.8–815.9 nM. The structure activity relationship study for the 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides against these isoforms was also inferred from the results.

Small Molecule Microarray Based Discovery of PARP14 Inhibitors

Peng, Bo,Thorsell, Ann-Gerd,Karlberg, Tobias,Schüler, Herwig,Yao, Shao Q.

supporting information, p. 248 - 253 (2016/12/30)

Poly(ADP-ribose) polymerases (PARPs) are key enzymes in a variety of cellular processes. Most small-molecule PARP inhibitors developed to date have been against PARP1, and suffer from poor selectivity. PARP14 has recently emerged as a potential therapeutic target, but its inhibitor development has trailed behind. Herein, we describe a small molecule microarray-based strategy for high-throughput synthesis, screening of >1000 potential bidentate inhibitors of PARPs, and the successful discovery of a potent PARP14 inhibitor H10 with >20-fold selectivity over PARP1. Co-crystallization of the PARP14/H10 complex indicated H10 bound to both the nicotinamide and the adenine subsites. Further structure–activity relationship studies identified important binding elements in the adenine subsite. In tumor cells, H10 was able to chemically knockdown endogenous PARP14 activities.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 2267-40-5